# A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy

> **NCT07688291** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Carcinoma Cell

## Interventions

- **DRUG:** PD-1/IL-2α-bias bispecific antibody fusion protein

## Key facts

- **NCT ID:** NCT07688291
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688291, "A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*